# First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3)

> **NCT03011528** · PHASE2 · COMPLETED · sponsor: **Institut Curie** · enrollment: 45 (actual)

## Conditions studied

- Ewing Sarcoma Family of Tumors

## Interventions

- **DRUG:** VDC-IE x2
- **DRUG:** VDC-IE
- **DRUG:** TEMIRI
- **DRUG:** Consolidation BuMel
- **DRUG:** Maintenance
- **PROCEDURE:** Local treatment by surgery
- **RADIATION:** Local treatment by radiotherapy

## Key facts

- **NCT ID:** NCT03011528
- **Lead sponsor:** Institut Curie
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-12
- **Primary completion:** 2022-08
- **Final completion:** 2023-11
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2025-11-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03011528

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03011528, "First-line Treatment of Ewing Tumours With Primary Extrapulmonary Dissemination in Patients From 2 to 50 Years (CombinaiR3)". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03011528. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*